PE20011012A1 - Benzoxa y benzotiazoles como inhibidores de sulfatasa de esteroide - Google Patents

Benzoxa y benzotiazoles como inhibidores de sulfatasa de esteroide

Info

Publication number
PE20011012A1
PE20011012A1 PE2000001233A PE0012332000A PE20011012A1 PE 20011012 A1 PE20011012 A1 PE 20011012A1 PE 2000001233 A PE2000001233 A PE 2000001233A PE 0012332000 A PE0012332000 A PE 0012332000A PE 20011012 A1 PE20011012 A1 PE 20011012A1
Authority
PE
Peru
Prior art keywords
benzoxa
benzothiazoles
compound
steroid sulfatase
ester
Prior art date
Application number
PE2000001233A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Billich
Barbara Wolff-Winiski
Erwin Paul Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927439.1A external-priority patent/GB9927439D0/en
Priority claimed from GB0007511A external-priority patent/GB0007511D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20011012A1 publication Critical patent/PE20011012A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2000001233A 1999-11-19 2000-11-17 Benzoxa y benzotiazoles como inhibidores de sulfatasa de esteroide PE20011012A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9927439.1A GB9927439D0 (en) 1999-11-19 1999-11-19 Organic compounds
GB0007511A GB0007511D0 (en) 2000-03-28 2000-03-28 Organic compounds

Publications (1)

Publication Number Publication Date
PE20011012A1 true PE20011012A1 (es) 2001-10-02

Family

ID=26243976

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001233A PE20011012A1 (es) 1999-11-19 2000-11-17 Benzoxa y benzotiazoles como inhibidores de sulfatasa de esteroide

Country Status (15)

Country Link
US (1) US6716865B1 (enExample)
EP (1) EP1230227B1 (enExample)
JP (1) JP2003514806A (enExample)
AR (1) AR026504A1 (enExample)
AT (1) ATE269853T1 (enExample)
AU (1) AU1857701A (enExample)
CO (1) CO5261573A1 (enExample)
DE (1) DE60011801T2 (enExample)
DK (1) DK1230227T3 (enExample)
ES (1) ES2223620T3 (enExample)
HK (1) HK1049329B (enExample)
PE (1) PE20011012A1 (enExample)
PT (1) PT1230227E (enExample)
TR (1) TR200402432T4 (enExample)
WO (1) WO2001036398A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR041952A1 (es) * 2002-11-14 2005-06-01 Novartis Ag N-sulfonilaminotiazol
DE10260955A1 (de) * 2002-12-20 2004-07-08 Henkel Kgaa Verwendung von Steroidsulfatase-Inhibitoren zur Verminderung von Haarausfall
CA2949336C (en) 2007-08-02 2018-11-06 Lei Zhu Process for the synthesis of e1 activating enzyme inhibitors
KR20100068287A (ko) 2007-09-17 2010-06-22 쁘레글렘 에스.아. 폐경기 전 여성의 에스트로겐 의존성 질환의 치료
CN104926730B (zh) * 2014-03-21 2017-07-21 中国科学院武汉岩土力学研究所 一种松香基咪唑啉类化合物及其合成方法和应用
WO2018052967A1 (en) * 2016-09-13 2018-03-22 Arbutus Biopharma, Inc. Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868800A (en) 1954-10-13 1959-01-13 Upjohn Co 6-ethoxybenzothiazole-2-sulfonamide
US4472418A (en) * 1983-04-22 1984-09-18 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
PT94305B (pt) * 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU3221993A (en) 1991-11-27 1993-06-28 Phanos Technologies, Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US5559127A (en) 1992-10-14 1996-09-24 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2202273A1 (en) 1994-10-12 1996-04-25 David J. Cavalla Novel benzoxazoles
US6169085B1 (en) * 1995-03-10 2001-01-02 G. D. Searle & Company Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
US5709845A (en) 1996-05-13 1998-01-20 Rajagopalan; Raghavan Tricyclic functional dyes for contrast enhancement in optical imaging
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
JPH10237053A (ja) 1997-02-24 1998-09-08 Sumitomo Chem Co Ltd ベンゾチアゾール類の製造方法
US6140051A (en) 1997-07-21 2000-10-31 Promega Biosciences, Inc. Fluorescent dibenzazole derivatives and methods related thereto
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
RU2227458C2 (ru) 1998-06-18 2004-04-27 Новартис Аг Применение бензазольных соединений в качестве репеллента, композиция их содержащая и способ получения композиции

Also Published As

Publication number Publication date
EP1230227B1 (en) 2004-06-23
ES2223620T3 (es) 2005-03-01
US6716865B1 (en) 2004-04-06
CO5261573A1 (es) 2003-03-31
AU1857701A (en) 2001-05-30
TR200402432T4 (tr) 2004-12-21
DK1230227T3 (da) 2004-08-16
HK1049329A1 (en) 2003-05-09
DE60011801T2 (de) 2005-07-14
JP2003514806A (ja) 2003-04-22
PT1230227E (pt) 2004-10-29
EP1230227A1 (en) 2002-08-14
HK1049329B (en) 2005-03-24
DE60011801D1 (de) 2004-07-29
ATE269853T1 (de) 2004-07-15
WO2001036398A1 (en) 2001-05-25
AR026504A1 (es) 2003-02-12

Similar Documents

Publication Publication Date Title
PE20000419A1 (es) Derivados de cromanona y tiocromanona
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
PE20000986A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
ES2032452T3 (es) Analogos oxidados de carbomoil-4-aza-5alfa-androst-1-en-3-ona 17beta-n-monosustituidos. (reserva del art. 167.2 cpe).
EP2067784A3 (en) 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
CO5560610A2 (es) Derivados de yodobenzopiran-4-ona que tienen actividad fungicida
PE20050480A1 (es) Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados
PE110899A1 (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
PE20010546A1 (es) Uso de una composicion de benzoheterociclos como inhibidores de mek para tratar el dolor cronico
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
BR9206861A (pt) Derivados de piperazina como antagonistas de 5-HT1A
PE20010208A1 (es) Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos
PE20010330A1 (es) Androgenos oralmente activos
PE20011012A1 (es) Benzoxa y benzotiazoles como inhibidores de sulfatasa de esteroide
PE20000755A1 (es) Derivados ftalacinicos inhibidores de la fosfodiesterasa 4
PE20010678A1 (es) Tratamiento de enfisema usando antagonistas retinoides selectivos de rar
CO5031309A1 (es) Composiciones mezcladas de activadores de peroxidos
CO4990932A1 (es) Derivados de 2,1,3-benzotiadiazol y proceso para su preparacion
PE20030548A1 (es) Acilsulfonamidas como inhibidores de sulfatasa esteroide
GB8622330D0 (en) 4-substituted 6-alkylidenandrostene-3,17-dione derivatives
DE69410081D1 (de) Zwischenprodukte für die Herstellung von Endothelinrezeptor-Antagonist-Triterpen-Derivaten
PE20001468A1 (es) Compuestos no peptidicos como secretagogos de la hormona del crecimiento
ES8203848A1 (es) Procedimiento para preparar derivados de acido acetico
PE20001563A1 (es) Antagonistas del receptor de vitronectina
NZ505200A (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal